IP Library Granted Patent US 10,934,569
Granted Patent B1
US 10,934,569 · App. 16/226,963 · Granted Mar 2, 2021

Enzymatic processes for synthesizing RNA containing certain non-standard nucleotides

Inventors: Nicole A Leal (Gainesville, FL); Steven A Benner (Gainesville, FL)
C12P19/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,934,569
App. No.
16/226,963
Granted
Mar 2, 2021
Kind
B1
Abstract

This invention relates to processes that transcribe DNA molecules containing non-standard nucleotides using variants of T7 RNA polymerase to give RNA transcripts that contain their complementary non-standard nucleotides. Non-standard nucleotides pair during transcription using patterns of hydrogen bonding that are different from patterns that join the thymine-adenine and guanine-cytosine nucleobase pairs.

Claims (15)

1. A process for synthesizing RNA containing one or more non-standard nucleotides, wherein said process

comprises contacting in aqueous solution

(a) a variant of T7 RNA polymerase that can accept non-standard nucleoside triphosphates that do not present electron density to the minor groove with

(b) a DNA template comprising a promoter for said variant, and

(c) nucleoside triphosphates that

comprise one or more independently selected heterocycles selected from the group consisting of

wherein M is an alkyl, alkenyl, or alkynyl substituent, either simple or functionalized, and R is the point of attachment of said heterocycle(s) to the ribose ring of said nucleoside triphosphate(s).

2. The process of claim 1 , wherein said variant to T7 RNA polymerase has amino acids replaced at individual sites in its polypeptide sequence, wherein said replacements comprise a replacement of tyrosine at position 639 by phenylalanine, a replacement of histidine at position 784 by alanine, and a replacement of proline at position 266 by leucine.

3. The process of claim 1 , wherein said nucleoside triphosphates comprise one or more independently selected heterocycles selected from the group consisting of

and M is an alkyl, alkenyl, or alkynyl substituent, either simple or functionalized, and R is the point of attachment of said heterocycle(s) to the ribose ring of said nucleoside triphosphate(s).

4. The process of claim 3 , wherein M is methyl.

5. The process of claim 1 , wherein said nucleoside triphosphates comprise one or more independently selected heterocycles selected from the group consisting of

and R is the point of attachment of said heterocycle(s) to the ribose ring of said nucleoside triphosphate(s).

6. The process of claim 1 , wherein said nucleoside triphosphate(s) comprise(s) the heterocycle

wherein R is the point of attachment of said heterocycle(s) to the ribose ring of said nucleoside triphosphate(s).

Assignments (1)
CONFIRMATORY LICENSE Recorded May 28, 2020
From: FOUNDATION FOR APPLIED MOLECULAR EVOLUTION INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052774/0699 →